Limits the substitution of abuse-deterrent analgesic opioid drug products for analgesic opioids lacking such technology
Summary
Provides for patient access to FDA approved abuse-deterrent technology to help combat opioid abuse.
Bill status
passed
3 of 5 stages cleared
Introduction
Feb 2021
Committee Review
May 2022
Senate Passage
May 2022
Assembly Passage
Governor
Introduced Feb 5, 2021
Last action May 25, 2022
Floor votes · Senate May 25, 2022
How they voted
60–1
Passed · 2 other
Total votes 63
May 25, 2022
D
Democratic43
95% Yea
R
Republican20
95% Yea
Vote distribution
All Yea
All Nay
Mixed
No data
Full legislative history
Actions timeline
Total actions
16
Key actions
2
Committee
6
May 25, 2022
Committee
REFERRED TO INSURANCE
lower
May 25, 2022
Upper · Passed
PASSED SENATE
upper
May 16, 2022
Committee
COMMITTEE DISCHARGED AND COMMITTED TO RULES
upper
Jan 19, 2022
Committee
REPORTED AND COMMITTED TO FINANCE
upper
Jan 5, 2022
Committee
REFERRED TO HEALTH
upper
May 4, 2021
Committee
REFERRED TO INSURANCE
lower
May 4, 2021
Upper · Passed
PASSED SENATE
upper
Feb 5, 2021
Committee
REFERRED TO HEALTH
upper
1 primary · 0 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Samra Brouk
DDemocratic/Working Families
Ask Maddy
·
AI policy assistant
Ask Maddy about S 4532
Scope: NY
Hi! I can help you understand S 4532. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline